[NEWS RELEASEystar Bio-Pharmaceutical Reports First Quarter 2011 Results $7.0 Million Top Line; $0.27 Diluted EPS; Reiterates Fiscal 2011 Top Line Guidance range of $60 Million to $63 Million XIAN, CHINA May 23, 2011 --Skystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ( First Quarter 2011 Highlights Revenuereases 46% YoY to $7.0 million Veterinary vaccines totaled $0.3 million, up 30% YoY]
[NEWS RELEASEystar Bio-Pharmaceutical Reports First Quarter 2011 Results $7.0 Million Top Line; $0.27 Diluted EPS; Reiterates Fiscal 2011 Top Line Guidance range of $60 Million to $63 Million XIAN, CHINA May 23, 2011 --Skystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ( First Quarter 2011 Highlights Revenuereases 46% YoY to $7.0 million Veterinary vaccines totaled $0.3 million, up 30% YoY]
[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer May 23, 2011 EX-32.1 5 v223770_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer May 23, 2011 EX-32.2 6 v223770_ex32-2.htm]
[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer May 23, 2011 EX-32.1 5 v223770_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer May 23, 2011 EX-32.2 6 v223770_ex32-2.htm]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page No. 3 PART I.FINANCIAL INFORMATION 4 Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of March 31, 2011 (unaudited) and December 31, 2010 4ndensednsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months Ended March 31, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer May 23, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer May 23, 2011]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page No. 3 PART I.FINANCIAL INFORMATION 4 Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of March 31, 2011 (unaudited) and December 31, 2010 4ndensednsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months Ended March 31, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Michael H. Lan, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer May 23, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer May 23, 2011]
[TPI Reports Record Third Quarter Fiscal Year 2011 Financial Results May 16, 2011 CHENGDU, China, May 16, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the third quarter of Fiscal Year 2011. Third quarter fiscal] [Tianyin Pharmaceutical, Inc. Third Quarter Fiscal Year 2011 Earnings Results May 17, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. And welcome to the Tianyin Pharmaceutical Incorporated Third Quarter 2011 Earnings Conference Call. At this time, all participants are in a listen-only mode, and following the presentation, instructions will be given for the question-and-answer session.] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 16, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Item 7.01. Regulation]
[TPI Reports Record Third Quarter Fiscal Year 2011 Financial Results May 16, 2011 CHENGDU, China, May 16, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the third quarter of Fiscal Year 2011. Third quarter fiscal] [Tianyin Pharmaceutical, Inc. Third Quarter Fiscal Year 2011 Earnings Results May 17, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. And welcome to the Tianyin Pharmaceutical Incorporated Third Quarter 2011 Earnings Conference Call. At this time, all participants are in a listen-only mode, and following the presentation, instructions will be given for the question-and-answer session.] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 16, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Item 7.01. Regulation]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code)] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, Inc. of our report dated March 24, 2011 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]
[FORM 10-K /A Amendment No. 1 (Mark One) x December 31, 2010 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code)] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161598) of Biostar Pharmaceuticals, Inc. of our report dated March 24, 2011 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of] [CERTIFICATION I, Ronghua Wang, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION I, Zack Pan, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]
